Portal de Periódicos da CAPES

Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse‐free survival

2010; Wiley; Volume: 25; Issue: 8 Linguagem: Inglês

10.1111/j.1468-3083.2010.03880.x

1468-3083

Anna Campanati, Lucia Sandroni, Rosaria Gesuita, A. Giuliano, Katia Giuliodori, Barbara Marconi, Giulia Ganzetti, Annamaria Offidani,

Botulinum Toxin and Related Neurological Disorders

Abstract Background No material about the identification of predictive clinical factors of therapeutic response to Botulinum Toxin Type A (BTX‐A) in focal idiopathic hyperhidrosis has been found. Objective To evaluate if age, sex, extension rate of hyperhidrotic area, localization, disease‐related impairment of life quality, number of previous local, non‐invasive treatments different from BTX‐A, and duration of disease, may affect the relapse‐free survival (RFS) after a BTX‐A treatment in palmar and axillary focal idiopathic hyperhidrosis. Methods Forty‐one patients suffering from palmar hyperhidrosis, and 38 patients suffering from axillary hyperhidrosis received intradermal injections of BTX‐A. All patients were clinically screened before and after treatment; they were followed for 15 months after it, according to Hyperhidrosis Disease Severity Scale (HDSS), Minor’s test, and DLQI test, to state disease severity, and disease‐related impairment of quality of life. Results The duration of therapeutic effect of BTX‐A is not significantly influenced by age ( P = 0.783), sex ( P = 0.762), extension of hyperhidrotic area ( P = 0.770), site of involvement ( P = 0.402), disease‐induced impairment of life quality ( P = 0.745), number of previous therapies ( P = 0.730), or site of involvement ( P = 0.402). In palmar idiopathic hyperhidrosis, patients with a longer disease history show a shorter duration of RFS after a treatment with BTX‐A ( P = 0.01). Conclusions Patients suffering from palmar hyperhidrosis have a longer lasting disease, and a length of disease more than 20 years in these patients influences the RFS after BTX‐A treatment.